Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03471572

NCT03471572
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You are willing and able to sign a written consent form to take part in the study
  • You are a woman aged 18 or older
  • You have been diagnosed with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (either recently or in the past)

Who may not be able to join:

  • You have a health condition that, in the doctor's opinion, could make it unsafe for you to complete the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
22 March 2018
Est. completion
21 December 2018

Where this trial is recruiting

🇮🇳 India

Primary endpoints

BRCA1 or BRCA2 mutation positive status

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov